DOCSLIB.ORG

Supplemental Figure 1. Gating Strategy for the Identification Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplemental Figure 1. Gating Strategy for the Identification Of 5 250K 250K 10 3 4 200K 200K 1 10 150K 150K 3 2 10 100K 100K PercPe710 β 0 50K 50K TCR SSC-A 0 0 FSC-A 0 50K 100K 150K 200K 250K 0 50K 100K 150K 200K 250K 0 103 104 105 FSC-A FSC-H Viability dye AQUA 5 10 4 4 10 4 10 5 3 3 10 10 0 0 CD4 APC H7 APC PLZF 0 103 104 105 0 103 104 105 Vα7.2 BV605 CD161 BV711 Supplemental Figure 1. Gating strategy for the identification of PLZF+ T cells among fetal tissues, representative intestinal sample shown. A B ** Naive Memory 100 5 10 80 MFI: 3403±1065 MFI: 4626±1347 4 10 60 3 10 MFI: 40 1417 0 20 PLZF APC PLZF ±930 0 103 104 105 MFI PLZF (% of Max) 0 CD161 BV711 PLZF- PLZF+ PLZF+ CD45RO+ Naive CD45RO+ C + + + - D PLZF CD161 PLZF CD161 30 **** *** 20±5 15±6 ** PLZF+ CD161+ PLZF+ CD161- 20 PLZF- TRM cells + 10 PLZF- adult PB % CD4 0 5 10 8±6 0±0 Small Large 4 Intestine Intestine 10 3 10 0 CD69 PE 0 103 104 105 CD103 FITC E MLN PLZF- SI PLZF- adult control 5 1±0 10 1±1 0±0 4 10 3 PercP e710 PercP 10 αβ 0 -3 10 TCR 10-3 0 103 104 105 Nur77 PE Supplemental Figure 2. Fetal PLZF+ CD4+ T cells display markers of resident memory T cells. (A) Representative flow plots of PLZF and CD161 staining among intestinal Naive (CD45RO-, CD45RA+, CCR7+) and memory (CD45RO+, CD45RA-) cells. The MFI (average ± SD) of PLZF is indicated for each population (n=7). (B) Normalized frequencies of PLZF MFI among indicated populations of intestinal Vα7.2- CD4+ TCRαβ+ cells. (C) Representative flow plots of CD69 and CD103 staining among intestinal TEM (CD45RA-, CCR7-) cells. Gating based on adult PBMCs. (D) Frequencies of resident memory T cells (TRM) (CD69+ CD103+) among fetal intestinal Vα7.2- CD4+ TCRαβ+ cells. (E) Representative flow plots of endogenous Nur77 expression among PLZF- CD4 T cells derived from fetal SI and MLN compared to adult PBMCs. Numbers in flow cytometry plots represent frequencies of gated populations ± SD. Circles represent individual donors. Box plot whiskers span minimum and maximum, line represents median. Kruskal Wallis paired ANOVA with Dunn’s multiple comparison test (B, D). **p < 0.01, ***p<0.001 ****p < 0.0001. Gated on Vα 7.2+ CD161hi TCRαβ+ A C PLZF+ T cells: Adult PB CD45RA- 61±11 0±0 CD161+ CD4+ IL-18R+ Vα7.2- PD-1+ CCR7- - PLZF T cells: Fetal small TCRαβ+ - intestine CD45RA 4±2 0±0 T cells CD161- IL-18R- - PD-1 7.2 BV605 semi-invariant α Vα7.2+ V innate T cells: MR1-5 OP RU PE MR1-5 6FP PE Vα7.2+ CD161+ B D post-sort purity: PLZF PLZF+ T cells SIIT cells + T cells T - PLZF- PLZF T cells T cells CCR7 CD45RA CD45RA CD161 CD161 CD161 CD161 PLZF + PLZF+ T cells PLZF T cells - T cells T SIIT cells IL-18R PLZF SIIT cells PD-1 Vα7.2 Vα7.2 IL-18R semi-invariant innate T cells T innate CD4 E ZBTB16 KLRB1 Vα7.2 5000 * 6000 ** 4000 * 3000 4000 IL-18R 2000 2000 CD161 1000 Norm. counts 0 Norm. counts 0 PLZF+ PLZF- SIIT PLZF+ PLZF- SIIT PDCD1 IL18R1 4000 ** 15000 ** 3000 10000 2000 5000 1000 Norm. counts 0 Norm. counts 0 PLZF+ PLZF- SIIT PLZF+ PLZF- SIIT Supplemental Figure 3. Characteristics of sorted fetal T cell populations. (A) Schematic representation of the strategy for the identification and isolation of sorted RNAseq T cell populations. (B) Sorting strategy for PLZF+ CD4+ T cells, PLZF- CD4+ T cells, and semi-invariant innate Vα7.2+ CD161+ T cells gated on live, TCRαβ+ intestinal T cells. (C) Representative flow plots of MAIT cell staining of adult PB (n=3) and fetal intestinal T cells (n=7). (D) Representative flow plots of post-sort purity after intra-nuclear staining for PLZF+ CD4+ T cells, PLZF- CD4+ T cells, and semi-invariant innate Vα7.2+ CD161+ T (SIIT) cells. (E) Boxplot quantification of RNAseq normalized read counts of indicated genes among sorted populations. *p<0.05, **p<0.01. Kruskal Wallis with Dunn’s multiple comparison test (E). A 1 1 1 1 1 1 1 1 1 1 1 1 AS AML F JUN IL32 IL7R SELL J CKLF ITGAE TGFB1 CXCR3 MAP3K8 TNFSF14 0 0 0 0 0 0 0 0 0 0 0 0 + CD4 T cells: 1 1 1 1 1 1 1 1 1 1 1 + PLZF - PLZF CD5 CD69 CD59 CD38 CCL5 CCR6 CCR4 CD226 ANXA1 BCL2A1 CD40LG 0 0 0 0 0 0 0 0 0 0 0 Cell type: Stem cells Lymphoid Correlation analysis: D Myeloid B Non-Immune Cluster 4 Cluste1 rs Myeloid-enriched Clusters: Cluste1 rs 32 0.54 TNF Cluster 1: 65 FURIN Lymphoid0 TGFB1 IFNGR1 Cluster 4: 0.5 CLEC7A Myeloid, EGR2 ID2 Lymphoid C3AR1 NLRP3 Cluster 6: JAK2 Stem cells GAB2 P2RY14 MAP3K8 Cluster 3: PTPN22 All cells BCL2A1 Cluster 5: REL ZC3H12A All cells TNFRSF9 NR4A3 Cluster 2: CST7 Myeloid CCL5 Spearman’s ρ 1 0.5 0 0.5 C E Cluster 2 C1: Immune response Myeloid- C2: Immune response enriched CSF1 C2: Lipid metabolism NFIL3 C3: Immune regulation DUSP5 ATF3 C4: Immune response NAMPT C5: Tissue development PTGS2 C6: Cell cycle MYO1E AHR 0 20 40 60 80 CAPG %genes in pathway PLIN2 LGALS3 ATP1B3 DAPK1 HIST1H2BK ISG15 Z-scale PPARG 3 2 1 0 -1 -2 SEC24D SERINC5 Supplemental Figure 4. Distinct transcriptional signature of fetal PLZF+ CD4+ T cells. (A) Normalized read counts of selected T cell memory- and activation-associated genes identified by RNAseq among sorted memory PLZF+ (red) and PLZF- (white) CD4+ T cells. (B) Correlation analysis using the Human Primary Cell Atlas as a reference of the differentially expressed genes (>2 fold, FDR<0.05) in PLZF+ CD4 T cells as compared to PLZF- CD4+ T cells revealing clusters of genes (C1-C6) that are co-expressed in the same cell types. (C) Pathway analysis of gene clusters identified by correlation analysis (B) was performed and gene pathways were organized into sub-clusters based on shared genes. Bar graphs show the % gene enrichment of each gene pathway within the indicated cluster. (D-E) Heatmap shows color-coded relative enrichment of differentially expressed genes in PLZF+ CD4+ T cells relative to PLZF- CD4+ T cells among indicated cell types identified from the Human Primary Cell Atlas for (D) Cluster 4 and (E) Cluster 2. Selected myeloid-en- riched genes involved in immune response and immune regulation are labeled. IFNγ TNFα A B ns SI PLZF+ CD161+ SI PLZF+ CD161- adult PB no PMA control 100 ns 5 10 TNFα IFNγ 80 4 57±28 43±26 20±11 0 10 60 3 10 40 PeCy7 α 0 20 TNF 28±10 20±8 9±6 0 % cytokine production 0 0 103 104 105 IFNγ FITC SI CD4+ PLZF+ PLZF+ T cells: CD161- CD161+ C D 40 15 Spearman ρ=0.35 Spearman ρ=0.34 cells p=0.15 + p=0.2 T T cells + 30 10 CD4 - CD4 - 20 PLZF + PLZF 5 α + γ 10 %TNF %IFN 0 0 17 18 19 20 21 22 23 17 18 19 20 21 22 23 GA (weeks) GA (weeks) E SI PLZF+ SI PLZF- adult PB 4 10 3 10 FITC γ 0 0±0 0±0 0.1±0 IFN 0 103 104 105 IL-10 Pe * F SI PLZF+ SI PLZF- no PMA control G 60 5 10 50 4 10 40 cells + 3 30 10 PeCy7 20 % IL-2 0 α 45±11 29±10 0±0 10 TNF 0 103 104 105 0 IL-2 FITC PLZF+ PLZF- T cells T cells H I SI PLZF+ SI PLZF- no PMA control 20 ns 5 10 15 4 10 cells + 3 10 10 % IL-8 FITC γ 5 0 8±3 8±6 0±0 IFN 0 103 104 105 0 IL-8 BV421 PLZF+ PLZF- T cells T cells Supplemental Figure 5. SI-PLZF+ CD4 T cells are poised for rapid production of Th1 cytokines. All samples gated on live Vα7.2- CD4+ TCRαβ+ cells. (A) Representative flow plots of intracellular TNFα and IFNγ staining of indicated populations (n=18) after PMA/Ionomycin stimulation of small intestine (SI) compared to adult PB CD4+ T cells. Gates drawn on unstimulated control. (B) Frequencies of IFNγ+ and TNFα+ cells within indicated populations of SI-PLZF+ CD4+ T cells after PMA/Ionomycin stimulation. (C, D) Association between gestational age (GA) and (C) IFNγ and (D) TNFα production by SI PLZF- CD4+ T cells in response to PMA/Ionomycin, Spearman’s rank correlation. Circles represent individual donors. (E) Representative flow plots of intracellular IL-10 expression after PMA/Ionomycin stimulation within indicated populations of SI CD4 T cells (n=5). (F, H) Representative flow plots of intracellular (F) IL-2 and (H) IL-8 after PMA/Ionomycin stimulation within indicated populations of SI CD4 T cells. Gates drawn on unstimulated control. (G, I) Frequencies of (G) IL-2+ and (I) IL-8+ cells within indicated populations of SI CD4 T cells after PMA/Ionomycin stimulation. Numbers in the flow cytometry plots correspond to the mean ± SD of gated frequencies. Circles represent individual donors. Box plot whiskers span minimum and maximum, line represents median. Kruskal Wallis paired ANOVA with Dunn’s multiple comparison test (B), Wilcoxon matched-pairs signed rank test (G, I).
Load more

Recommended publications
  • New Insights Into Epididymal Function in Relation to Sperm Maturation
    REPRODUCTIONREVIEW New insights into epididymal function in relation to sperm maturation Jean-Louis Dacheux and Franc¸oise Dacheux UMR INRA-CNRS 7247, 37380 Nouzilly, France Correspondence should be addressed to J-L Dacheux; Email: [email protected] Abstract Testicular spermatozoa acquire fertility only after 1 or 2 weeks of transit through the epididymis. At the end of this several meters long epididymal tubule, the male gamete is able to move, capacitate, migrate through the female tract, bind to the egg membrane and fuse to the oocyte to result in a viable embryo. All these sperm properties are acquired after sequential modifications occurring either at the level of the spermatozoon or in the epididymal surroundings. Over the last few decades, significant increases in the understanding of the composition of the male gamete and its surroundings have resulted from the use of new techniques such as genome sequencing, proteomics combined with high-sensitivity mass spectrometry, and gene-knockout approaches. This review reports and discusses the most relevant new results obtained in different species regarding the various cellular processes occurring at the sperm level, in particular, those related to the development of motility and egg binding during epididymal transit. Reproduction (2014) 147 R27–R42 Introduction sequentially throughout the epididymis. In view of these two parallel events, most investigations have The formation of fertile spermatozoa is the result of involved assessing the relationships between these two spectacular stages of cell differentiation that begin in events and identifying the epididymal signals able to the male gonad and finish in the female tract. The control spermatozoon fertility.
    [Show full text]
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
    [Show full text]
  • Immune Regulation by CD52-Expressing CD4 T Cells
    Cellular & Molecular Immunology (2013) 10, 379–382 ß 2013 CSI and USTC. All rights reserved 1672-7681/13 $32.00 www.nature.com/cmi RESEARCH HIGHLIGHT Immune regulation by CD52-expressing CD4 T cells Ban-Hock Toh1, Tin Kyaw1,2, Peter Tipping1 and Alex Bobik2 T-cell regulation by CD52-expressing CD4 T cells appears to operate by two different and possibly synergistic mechanisms. The first is by its release from the cell surface of CD4 T cells that express high levels of CD52 that then binds to the inhibitory sialic acid-binding immunoglobulin-like lectins-10 (Siglec-10) receptor to attenuate effector T-cell activation by impairing phosphorylation of T-cell receptor associated lck and zap-70. The second mechanism appears to be by crosslinkage of the CD52 molecules by an as yet unidentified endogenous ligand that is mimicked by a bivalent anti-CD52 antibody that results in their expansion. Cellular & Molecular Immunology (2013) 10, 379–382; doi:10.1038/cmi.2013.35; published online 12 August 2013 he immune system is designed to appears in the affirmative, and includes suppression was lost by cleavage of N- T protect its host from invading players such as IL-10-secreting Tr1 and glycans from CD52-Fc by peptide N- pathogens and yet remain non-reactive TGF-b-secreting Th3. cells. Absence of glycosidase or by removal of sialic acid to self. Immunological homeostasis is surface markers limited the usefulness residues by neuraminidase. Suppression maintained by purging self-reactive lym- of these other regulators. However, the was also blocked by antibody to the phocytes by clonal deletion coupled with recent report that CD49b and lympho- extracellular domain of Siglec-10 and a regulatory population of lymphocytes cyte activation gene-3 are highly and sta- by soluble Siglec-10-Fc.
    [Show full text]
  • Identification and Characterization of RHOA-Interacting Proteins in Bovine Spermatozoa1
    BIOLOGY OF REPRODUCTION 78, 184–192 (2008) Published online before print 10 October 2007. DOI 10.1095/biolreprod.107.062943 Identification and Characterization of RHOA-Interacting Proteins in Bovine Spermatozoa1 Sarah E. Fiedler, Malini Bajpai, and Daniel W. Carr2 Department of Medicine, Oregon Health & Sciences University and Veterans Affairs Medical Center, Portland, Oregon 97239 ABSTRACT Guanine nucleotide exchange factors (GEFs) catalyze the GDP for GTP exchange [2]. Activation is negatively regulated by In somatic cells, RHOA mediates actin dynamics through a both guanine nucleotide dissociation inhibitors (RHO GDIs) GNA13-mediated signaling cascade involving RHO kinase and GTPase-activating proteins (GAPs) [1, 2]. Endogenous (ROCK), LIM kinase (LIMK), and cofilin. RHOA can be RHO can be inactivated via C3 exoenzyme ADP-ribosylation, negatively regulated by protein kinase A (PRKA), and it and studies have demonstrated RHO involvement in actin-based interacts with members of the A-kinase anchoring (AKAP) cytoskeletal response to extracellular signals, including lyso- family via intermediary proteins. In spermatozoa, actin poly- merization precedes the acrosome reaction, which is necessary phosphatidic acid (LPA) [2–4]. LPA is known to signal through for normal fertility. The present study was undertaken to G-protein-coupled receptors (GPCRs) [4, 5]; specifically, LPA- determine whether the GNA13-mediated RHOA signaling activated GNA13 (formerly Ga13) promotes RHO activation pathway may be involved in acrosome reaction in bovine through GEFs [4, 6]. Activated RHO-GTP then signals RHO caudal sperm, and whether AKAPs may be involved in its kinase (ROCK), resulting in the phosphorylation and activation targeting and regulation. GNA13, RHOA, ROCK2, LIMK2, and of LIM-kinase (LIMK), which in turn phosphorylates and cofilin were all detected by Western blot in bovine caudal inactivates cofilin, an actin depolymerizer, the end result being sperm.
    [Show full text]
  • Supplementary Table S5. Differentially Expressed Gene Lists of PD-1High CD39+ CD8 Tils According to 4-1BB Expression Compared to PD-1+ CD39- CD8 Tils
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer Supplementary Table S5. Differentially expressed gene lists of PD-1high CD39+ CD8 TILs according to 4-1BB expression compared to PD-1+ CD39- CD8 TILs Up- or down- regulated genes in Up- or down- regulated genes Up- or down- regulated genes only PD-1high CD39+ CD8 TILs only in 4-1BBneg PD-1high CD39+ in 4-1BBpos PD-1high CD39+ CD8 compared to PD-1+ CD39- CD8 CD8 TILs compared to PD-1+ TILs compared to PD-1+ CD39- TILs CD39- CD8 TILs CD8 TILs IL7R KLRG1 TNFSF4 ENTPD1 DHRS3 LEF1 ITGA5 MKI67 PZP KLF3 RYR2 SIK1B ANK3 LYST PPP1R3B ETV1 ADAM28 H2AC13 CCR7 GFOD1 RASGRP2 ITGAX MAST4 RAD51AP1 MYO1E CLCF1 NEBL S1PR5 VCL MPP7 MS4A6A PHLDB1 GFPT2 TNF RPL3 SPRY4 VCAM1 B4GALT5 TIPARP TNS3 PDCD1 POLQ AKAP5 IL6ST LY9 PLXND1 PLEKHA1 NEU1 DGKH SPRY2 PLEKHG3 IKZF4 MTX3 PARK7 ATP8B4 SYT11 PTGER4 SORL1 RAB11FIP5 BRCA1 MAP4K3 NCR1 CCR4 S1PR1 PDE8A IFIT2 EPHA4 ARHGEF12 PAICS PELI2 LAT2 GPRASP1 TTN RPLP0 IL4I1 AUTS2 RPS3 CDCA3 NHS LONRF2 CDC42EP3 SLCO3A1 RRM2 ADAMTSL4 INPP5F ARHGAP31 ESCO2 ADRB2 CSF1 WDHD1 GOLIM4 CDK5RAP1 CD69 GLUL HJURP SHC4 GNLY TTC9 HELLS DPP4 IL23A PITPNC1 TOX ARHGEF9 EXO1 SLC4A4 CKAP4 CARMIL3 NHSL2 DZIP3 GINS1 FUT8 UBASH3B CDCA5 PDE7B SOGA1 CDC45 NR3C2 TRIB1 KIF14 TRAF5 LIMS1 PPP1R2C TNFRSF9 KLRC2 POLA1 CD80 ATP10D CDCA8 SETD7 IER2 PATL2 CCDC141 CD84 HSPA6 CYB561 MPHOSPH9 CLSPN KLRC1 PTMS SCML4 ZBTB10 CCL3 CA5B PIP5K1B WNT9A CCNH GEM IL18RAP GGH SARDH B3GNT7 C13orf46 SBF2 IKZF3 ZMAT1 TCF7 NECTIN1 H3C7 FOS PAG1 HECA SLC4A10 SLC35G2 PER1 P2RY1 NFKBIA WDR76 PLAUR KDM1A H1-5 TSHZ2 FAM102B HMMR GPR132 CCRL2 PARP8 A2M ST8SIA1 NUF2 IL5RA RBPMS UBE2T USP53 EEF1A1 PLAC8 LGR6 TMEM123 NEK2 SNAP47 PTGIS SH2B3 P2RY8 S100PBP PLEKHA7 CLNK CRIM1 MGAT5 YBX3 TP53INP1 DTL CFH FEZ1 MYB FRMD4B TSPAN5 STIL ITGA2 GOLGA6L10 MYBL2 AHI1 CAND2 GZMB RBPJ PELI1 HSPA1B KCNK5 GOLGA6L9 TICRR TPRG1 UBE2C AURKA Leem G, et al.
    [Show full text]
  • G-Protein-Coupled Receptor Signaling and Polarized Actin Dynamics Drive
    RESEARCH ARTICLE elifesciences.org G-protein-coupled receptor signaling and polarized actin dynamics drive cell-in-cell invasion Vladimir Purvanov, Manuel Holst, Jameel Khan, Christian Baarlink, Robert Grosse* Institute of Pharmacology, University of Marburg, Marburg, Germany Abstract Homotypic or entotic cell-in-cell invasion is an integrin-independent process observed in carcinoma cells exposed during conditions of low adhesion such as in exudates of malignant disease. Although active cell-in-cell invasion depends on RhoA and actin, the precise mechanism as well as the underlying actin structures and assembly factors driving the process are unknown. Furthermore, whether specific cell surface receptors trigger entotic invasion in a signal-dependent fashion has not been investigated. In this study, we identify the G-protein-coupled LPA receptor 2 (LPAR2) as a signal transducer specifically required for the actively invading cell during entosis. We find that 12/13G and PDZ-RhoGEF are required for entotic invasion, which is driven by blebbing and a uropod-like actin structure at the rear of the invading cell. Finally, we provide evidence for an involvement of the RhoA-regulated formin Dia1 for entosis downstream of LPAR2. Thus, we delineate a signaling process that regulates actin dynamics during cell-in-cell invasion. DOI: 10.7554/eLife.02786.001 Introduction Entosis has been described as a specialized form of homotypic cell-in-cell invasion in which one cell actively crawls into another (Overholtzer et al., 2007). Frequently, this occurs between tumor cells such as breast, cervical, or colon carcinoma cells and can be triggered by matrix detachment (Overholtzer et al., 2007), suggesting that loss of integrin-mediated adhesion may promote cell-in-cell invasion.
    [Show full text]
  • Congenital Microcephaly
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Sussex Research Online American Journal of Medical Genetics Part C (Seminars in Medical Genetics) ARTICLE Congenital Microcephaly DIANA ALCANTARA AND MARK O'DRISCOLL* The underlying etiologies of genetic congenital microcephaly are complex and multifactorial. Recently, with the exponential growth in the identification and characterization of novel genetic causes of congenital microcephaly, there has been a consolidation and emergence of certain themes concerning underlying pathomechanisms. These include abnormal mitotic microtubule spindle structure, numerical and structural abnormalities of the centrosome, altered cilia function, impaired DNA repair, DNA Damage Response signaling and DNA replication, along with attenuated cell cycle checkpoint proficiency. Many of these processes are highly interconnected. Interestingly, a defect in a gene whose encoded protein has a canonical function in one of these processes can often have multiple impacts at the cellular level involving several of these pathways. Here, we overview the key pathomechanistic themes underlying profound congenital microcephaly, and emphasize their interconnected nature. © 2014 Wiley Periodicals, Inc. KEY WORDS: cell division; mitosis; DNA replication; cilia How to cite this article: Alcantara D, O'Driscoll M. 2014. Congenital microcephaly. Am J Med Genet Part C Semin Med Genet 9999:1–16. INTRODUCTION mid‐gestation although glial cell division formation of the various cortical layers. and consequent brain volume enlarge- Furthermore, differentiating and devel- Congenital microcephaly, an occipital‐ ment does continue after birth [Spalding oping neurons must migrate to their frontal circumference of equal to or less et al., 2005]. Impaired neurogenesis is defined locations to construct the com- than 2–3 standard deviations below the therefore most obviously reflected clini- plex architecture and laminar layered age‐related population mean, denotes cally as congenital microcephaly.
    [Show full text]
  • High Throughput Strategies Aimed at Closing the GAP in Our Knowledge of Rho Gtpase Signaling
    cells Review High Throughput strategies Aimed at Closing the GAP in Our Knowledge of Rho GTPase Signaling Manel Dahmene 1, Laura Quirion 2 and Mélanie Laurin 1,3,* 1 Oncology Division, CHU de Québec–Université Laval Research Center, Québec, QC G1V 4G2, Canada; [email protected] 2 Montréal Clinical Research Institute (IRCM), Montréal, QC H2W 1R7, Canada; [email protected] 3 Université Laval Cancer Research Center, Québec, QC G1R 3S3, Canada * Correspondence: [email protected] Received: 21 May 2020; Accepted: 7 June 2020; Published: 9 June 2020 Abstract: Since their discovery, Rho GTPases have emerged as key regulators of cytoskeletal dynamics. In humans, there are 20 Rho GTPases and more than 150 regulators that belong to the RhoGEF, RhoGAP, and RhoGDI families. Throughout development, Rho GTPases choregraph a plethora of cellular processes essential for cellular migration, cell–cell junctions, and cell polarity assembly. Rho GTPases are also significant mediators of cancer cell invasion. Nevertheless, to date only a few molecules from these intricate signaling networks have been studied in depth, which has prevented appreciation for the full scope of Rho GTPases’ biological functions. Given the large complexity involved, system level studies are required to fully grasp the extent of their biological roles and regulation. Recently, several groups have tackled this challenge by using proteomic approaches to map the full repertoire of Rho GTPases and Rho regulators protein interactions. These studies have provided in-depth understanding of Rho regulators specificity and have contributed to expand Rho GTPases’ effector portfolio. Additionally, new roles for understudied family members were unraveled using high throughput screening strategies using cell culture models and mouse embryos.
    [Show full text]
  • Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
    Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
    [Show full text]
  • (P -Value<0.05, Fold Change≥1.4), 4 Vs. 0 Gy Irradiation
    Table S1: Significant differentially expressed genes (P -Value<0.05, Fold Change≥1.4), 4 vs. 0 Gy irradiation Genbank Fold Change P -Value Gene Symbol Description Accession Q9F8M7_CARHY (Q9F8M7) DTDP-glucose 4,6-dehydratase (Fragment), partial (9%) 6.70 0.017399678 THC2699065 [THC2719287] 5.53 0.003379195 BC013657 BC013657 Homo sapiens cDNA clone IMAGE:4152983, partial cds. [BC013657] 5.10 0.024641735 THC2750781 Ciliary dynein heavy chain 5 (Axonemal beta dynein heavy chain 5) (HL1). 4.07 0.04353262 DNAH5 [Source:Uniprot/SWISSPROT;Acc:Q8TE73] [ENST00000382416] 3.81 0.002855909 NM_145263 SPATA18 Homo sapiens spermatogenesis associated 18 homolog (rat) (SPATA18), mRNA [NM_145263] AA418814 zw01a02.s1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE:767978 3', 3.69 0.03203913 AA418814 AA418814 mRNA sequence [AA418814] AL356953 leucine-rich repeat-containing G protein-coupled receptor 6 {Homo sapiens} (exp=0; 3.63 0.0277936 THC2705989 wgp=1; cg=0), partial (4%) [THC2752981] AA484677 ne64a07.s1 NCI_CGAP_Alv1 Homo sapiens cDNA clone IMAGE:909012, mRNA 3.63 0.027098073 AA484677 AA484677 sequence [AA484677] oe06h09.s1 NCI_CGAP_Ov2 Homo sapiens cDNA clone IMAGE:1385153, mRNA sequence 3.48 0.04468495 AA837799 AA837799 [AA837799] Homo sapiens hypothetical protein LOC340109, mRNA (cDNA clone IMAGE:5578073), partial 3.27 0.031178378 BC039509 LOC643401 cds. [BC039509] Homo sapiens Fas (TNF receptor superfamily, member 6) (FAS), transcript variant 1, mRNA 3.24 0.022156298 NM_000043 FAS [NM_000043] 3.20 0.021043295 A_32_P125056 BF803942 CM2-CI0135-021100-477-g08 CI0135 Homo sapiens cDNA, mRNA sequence 3.04 0.043389246 BF803942 BF803942 [BF803942] 3.03 0.002430239 NM_015920 RPS27L Homo sapiens ribosomal protein S27-like (RPS27L), mRNA [NM_015920] Homo sapiens tumor necrosis factor receptor superfamily, member 10c, decoy without an 2.98 0.021202829 NM_003841 TNFRSF10C intracellular domain (TNFRSF10C), mRNA [NM_003841] 2.97 0.03243901 AB002384 C6orf32 Homo sapiens mRNA for KIAA0386 gene, partial cds.
    [Show full text]
  • Constitutive Expression of Murine Ctla4ig from a Recombinant Adenovirus Vector Results in Prolonged Transgene Expression
    Gene Therapy (1997) 4, 853–860 1997 Stockton Press All rights reserved 0969-7128/97 $12.00 Constitutive expression of murine CTLA4Ig from a recombinant adenovirus vector results in prolonged transgene expression DB Schowalter1, L Meuse1, CB Wilson2,3, PS Linsley4 and MA Kay1,2,5,6 1Division of Medical Genetics, Department of Medicine, and Departments of 2Pediatrics, 3Immunology, 6Biochemistry and 5Pathology, University of Washington; and 4Bristol-Myers Squibb Pharmaceuticals, Seattle, WA, USA The administration of soluble muCTLA4Ig around the time Ad.RSV-muCTLA4Ig and a reporter adenovirus (2 × 109 of adenovirus vector mediated gene transfer into murine p.f.u. of Ad.PGK-hAAT) resulted in prolonged reporter hepatocytes has been shown to markedly prolong trans- gene expression, reduced anti-adenovirus and anti-hAAT gene expression, diminish the formation of adenovirus antibody production, and attenuated T cell proliferation and neutralizing antibody, decrease T cell proliferative IFN-g production in response to adenoviral vector. Mice response and infiltration into the liver without causing irre- given a constant total amount of adenovirus with dimin- versible systemic immunosuppression. In this study, an ishing amounts of Ad.RSV-muCTLA4Ig and a constant E1/E3-deleted adenovirus vector constitutively expressing amount of reporter virus (2 × 109 p.f.u. of Ad.PGK-hAAT) murine CTLA4Ig (Ad.RSV-muCTLA4Ig) was constructed in demonstrated prolonged reporter gene expression and order to determine if production of muCTLA4Ig from within decreased anti-adenovirus and anti-hAAT antibody pro- transduced cells (ie hepatocytes) would provide a more duction only when high serum levels of muCTLA4Ig were specific/localized interference with the CD28/B7–1 and produced.
    [Show full text]
  • A Novel Raji-Burkitt's Lymphoma Model for Preclinical and Mechanistic Evaluation of CD52-Targeted Immunotherapeutic Agents
    Cancer Therapy: Preclinical A Novel Raji-Burkitt’s Lymphoma Model for Preclinical and Mechanistic Evaluation of CD52-Targeted Immunotherapeutic Agents Rosa Lapalombella,1Xiaobin Zhao,1, 2 Georgia Triantafillou,1Bo Yu,3,4 Yan Jin, 4 Gerard Lozanski,5 Carolyn Cheney,1Nyla Heerema,5 David Jarjoura,6 Amy Lehman,6 L. James Lee,3,4 Guido Marcucci,1Robert J. Lee,2,4 Michael A. Caligiuri,1 Natarajan Muthusamy,1and John C. Byrd1, 2 Abstract Purpose:Todate, efforts to study CD52-targeted therapies, such as alemtuzumab, have beenlim- ited due to the lack of stable CD52 expressing transformed B-cell lines and animal models.We describe generation and utilization of cell lines that stably express CD52 both in vitro and in vivo. Experimental Design: By limiting dilution, we have established several clones of Raji-Burkitt’s lymphoma cell line that express surface CD52. Immunophenotype and cytogenetic charac- terizationof these clones was done. In vivo usefulness of the CD52high cell line to evaluate the ther- apeuticefficacyofCD52-directedantibody wasinvestigatedusingaSCIDmousexenograftmodel. Results: Stable expression of CD52 was confirmed in cells cultured in vitro up to 52 weeks of continuous growth. The functional integrity of the expressed CD52 molecule was shown using alemtuzumab, which induced cytotoxic effects in vitro in the CD52high but not the CD52low clone. Compared with control antibody, alemtuzumab treatment in CD52high inoculated mice resulted in significantly increased median survival. Comparable levels of CD52-targeted direct cyto- toxicity, complement-dependent cytotoxicity, and antibody-dependent cytotoxicity and anti-CD52 immunoliposome-mediated delivery of synthetic oligodeoxyribo nucleotides in CD52high clone and primary B-chronic lymphocytic leukemia cells implicated potential in vivo application of this model for evaluation of CD52-targeted antibody and immunoliposomes encapsulating therapeutic agents.
    [Show full text]